Optimal diuretic strategies in heart failure

被引:8
|
作者
Suri, Sarabjeet S. [1 ]
Pamboukian, Salpy V. [1 ]
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA
关键词
Heart failure (HF); diuresis; diuretic resistance; FUROSEMIDE; TOLVAPTAN;
D O I
10.21037/atm-20-4600
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Heart failure (HF) is one of the major causes of morbidity and mortality in the world. According to a 2019 American Heart Association report, about 6.2 million American adults had HF between 2013 and 2016, being responsible for almost 1 million admissions. As the population ages, the prevalence of HF is anticipated to increase, with 8 million Americans projected to have HF by 2030, posing a significant public health and financial burden. Acute decompensated HF (ADHF) is a syndrome characterized by volume overload and inadequate cardiac output associated with symptoms including some combination of exertional shortness of breath, orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue, tissue congestion (e.g., peripheral edema) and decreased mentation. The pathology is characterized by hemodynamic abnormalities that result in autonomic imbalance with an increase in sympathetic activity, withdrawal of vagal activity and neurohormonal activation (NA) resulting in increased plasma volume in the setting of decreased sodium excretion, increased water retention and in turn an elevation of filling pressures. These neurohormonal changes are adaptive mechanisms which in the short term are associated with increased contractility of the left ventricular (LV) and improvement in cardiac output. But chronically, the failing heart is unable to overcome the excessive pressure and volume leading to worsening HF. The primary symptomatic management of ADHF includes intravenous (IV) diuresis to help with decongestion and return to euvolemic status. Even though diuretics have not been shown to provide any mortality benefit, they have been clinically proven to be of significant benefit in the acute decompensated phase, as well as in chronic management of HF. Loop diuretics remain the mainstay of therapy for symptomatic management of HF with use of thiazide diuretics for synergistic effect in the setting of diuretic resistance. Poor diuretic efficacy has been linked with higher mortality and increased rehospitalizations.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Diuretic response in acute heart failure: clinical characteristics and prognostic significance
    Valente, Mattia A. E.
    Voors, Adriaan A.
    Damman, Kevin
    Van Veldhuisen, Dirk J.
    Massie, Barrie M.
    O'Connor, Christopher M.
    Metra, Marco
    Ponikowski, Piotr
    Teerlink, John R.
    Cotter, Gad
    Davison, Beth
    Cleland, John G. F.
    Givertz, Michael M.
    Bloomfield, Daniel M.
    Fiuzat, Mona
    Dittrich, Howard C.
    Hillege, Hans L.
    EUROPEAN HEART JOURNAL, 2014, 35 (19) : 1284 - +
  • [32] Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure
    Hirano, Daishi
    Kakegawa, Daisuke
    Yamada, Akifumi
    Ito, Akira
    Miwa, Saori
    Ida, Hiroyuki
    PEDIATRICS INTERNATIONAL, 2015, 57 (01) : 183 - 185
  • [33] Optimal diuretic dosing strategies following cardiac surgery: a retrospective cohort study
    O'Connell, Elizabeth
    Edwards, Nicola
    O'Connell, Matthew
    Kirmani, Bilal H.
    AME SURGICAL JOURNAL, 2024, 4
  • [34] Combination Diuretic Therapy in Severe Congestive Heart Failure
    Tom P. J. Dormans
    Paul G. G. Gerlag
    Frans G. M. Russel
    P. Smits
    Drugs, 1998, 55 : 165 - 172
  • [35] Basal natriuresis as a predictor of diuretic resistance and clinical evolution in acute heart failure
    Scatularo, Cristhian E.
    Battioni, Luciano
    Guazzone, Analia
    Esperon, Guillermina
    Corsico, Luciana
    Grancelli, Hugo O.
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (08)
  • [36] Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan
    Pose, A.
    Almenar, L.
    Manzano, L.
    Gavira, J. J.
    Lopez Granados, A.
    Delgado, J.
    Aramburu, O.
    Arevalo, J. C.
    Mendez, M.
    Comin, J.
    Manito, N.
    REVISTA CLINICA ESPANOLA, 2017, 217 (07): : 398 - 404
  • [37] Loop diuretic resistance complicating acute heart failure
    Zachary L. Cox
    Jeffrey M. Testani
    Heart Failure Reviews, 2020, 25 : 133 - 145
  • [38] Loop diuretic resistance complicating acute heart failure
    Cox, Zachary L.
    Testani, Jeffrey M.
    HEART FAILURE REVIEWS, 2020, 25 (01) : 133 - 145
  • [39] Prevalence and outcome of diuretic resistance in heart failure: reply
    Trullas, Joan-Carles
    Casado, Jesus
    Morales-Rull, Jose-Luis
    Formiga, Francesc
    Manzano, Luis
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (04) : 633 - 634
  • [40] Hypochloremia and Diuretic Resistance in Heart Failure Mechanistic Insights
    Hanberg, Jennifer S.
    Rao, Veena
    ter Maaten, Jozine M.
    Laur, Olga
    Brisco, Meredith A.
    Wilson, F. Perry
    Grodin, Justin L.
    Assefa, Mahlet
    Broughton, J. Samuel
    Planavsky, Noah J.
    Ahmad, Tariq
    Bellumkonda, Lavanya
    Tang, W. H. Wilson
    Parikh, Chirag R.
    Testani, Jeffrey M.
    CIRCULATION-HEART FAILURE, 2016, 9 (08)